Vaxcyte (PCVX) Competitors $41.79 +1.05 (+2.58%) As of 03:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCVX vs. GMAB, SMMT, ASND, VTRS, RDY, MRNA, ROIV, QGEN, ELAN, and BBIOShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. Its Competitors Genmab A/S Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Genmab A/S (NASDAQ:GMAB) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings. Which has more risk and volatility, GMAB or PCVX? Genmab A/S has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Which has stronger earnings and valuation, GMAB or PCVX? Genmab A/S has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.12B6.54$1.14B$1.9915.99VaxcyteN/AN/A-$463.93M-$4.11-10.17 Is GMAB or PCVX more profitable? Genmab A/S has a net margin of 37.53% compared to Vaxcyte's net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S37.53% 21.03% 16.98% Vaxcyte N/A -16.85%-15.92% Do institutionals and insiders hold more shares of GMAB or PCVX? 7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate GMAB or PCVX? Genmab A/S presently has a consensus target price of $40.80, suggesting a potential upside of 28.20%. Vaxcyte has a consensus target price of $106.25, suggesting a potential upside of 154.25%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Genmab A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82Vaxcyte 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Does the media refer more to GMAB or PCVX? In the previous week, Genmab A/S had 4 more articles in the media than Vaxcyte. MarketBeat recorded 10 mentions for Genmab A/S and 6 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.89 beat Genmab A/S's score of 0.81 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGenmab A/S beats Vaxcyte on 11 of the 16 factors compared between the two stocks. Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.44B$12.26B$9.05B$10.58BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-10.1921.6485.8427.32Price / SalesN/A275.72535.95201.92Price / CashN/A47.1237.9261.55Price / Book1.5810.4113.026.76Net Income-$463.93M-$52.40M$3.30B$275.79M7 Day Performance4.14%6.34%4.69%2.44%1 Month Performance27.72%16.09%9.86%8.86%1 Year Performance-62.64%33.38%84.90%35.45% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte2.4057 of 5 stars$41.79+2.6%$106.25+154.2%-63.5%$5.44BN/A-10.19160News CoverageGMABGenmab A/S4.3339 of 5 stars$33.31-0.7%$40.80+22.5%+38.8%$21.55B$3.12B16.742,682Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics3.1614 of 5 stars$22.15+3.4%$31.29+41.2%+18.5%$15.92B$700K-21.93110Analyst ForecastASNDAscendis Pharma A/S2.9535 of 5 stars$210.83+3.3%$244.36+15.9%+59.1%$12.59B$393.54M-40.861,017News CoverageAnalyst ForecastHigh Trading VolumeVTRSViatris1.6431 of 5 stars$10.13-0.6%$10.40+2.7%-11.9%$11.88B$14.74B-3.4932,000Analyst ForecastRDYDr. Reddy's Laboratories3.2019 of 5 stars$14.12-0.3%$16.95+20.0%-11.1%$11.82B$3.81B21.3927,811News CoveragePositive NewsAnalyst ForecastMRNAModerna4.3096 of 5 stars$27.54-3.3%$41.81+51.8%-52.2%$11.08B$3.24B-3.665,800Analyst ForecastROIVRoivant Sciences3.5759 of 5 stars$16.26+0.6%$19.94+22.6%+42.1%$11.04B$29.05M0.00860Analyst ForecastInsider TradeQGENQIAGEN4.3898 of 5 stars$46.99+0.4%$49.40+5.1%+12.8%$10.40B$1.98B27.765,765Analyst ForecastELANElanco Animal Health2.6802 of 5 stars$20.68+0.2%$18.33-11.3%+40.6%$10.25B$4.44B24.059,000Analyst UpgradeBBIOBridgeBio Pharma4.2182 of 5 stars$54.61+3.3%$63.94+17.1%+123.6%$10.11B$221.90M-13.35400Analyst Forecast Related Companies and Tools Related Companies Genmab A/S Competitors Summit Therapeutics Competitors Ascendis Pharma A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Roivant Sciences Competitors QIAGEN Competitors Elanco Animal Health Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCVX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
